Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.60 |
| ▸ | EGFR | P00533 | 15/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.47 |
| ▸ | FECH | P22830 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696913 | 0.96 | ERBB2 (0.58) | ERBB2EGFRKCNH2RIPK2YES1 | |
| SCHEMBL4385327 | 0.87 | ERBB2 (0.78) | ERBB2EGFRKCNH2 | |
| SCHEMBL4389133 | 0.86 | EGFR (0.65) | ERBB2EGFRKCNH2 | |
| SCHEMBL4383941 | 0.85 | EGFR (0.64) | ERBB2EGFRERBB4 | |
| SCHEMBL4387599 | 0.85 | ERBB2 (0.58) | ERBB2EGFRKCNH2 | |
| SCHEMBL4385319 | 0.84 | ERBB2 (0.64) | ERBB2EGFRKCNH2 | |
| SCHEMBL4544225 | 0.83 | ERBB2 (0.76) | ERBB2EGFRKCNH2 | |
| SCHEMBL5474732 | 0.83 | ERBB2 (0.76) | ERBB2EGFRKCNH2 | |
| SCHEMBL4396239 | 0.79 | ERBB2 (0.79) | ERBB2EGFRKCNH2 | |
| SCHEMBL4391670 | 0.79 | ERBB2 (0.79) | ERBB2EGFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | claimed |
| EP-1664029-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1664029-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | ERBB2 1/4885EGFR 3/4885KCNH2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.